欢迎访问电脑商情在线! 请免费注册
分享到





位置:首页 > 智能终端 > 文传商讯

Prestige BioPharma Announces Grand Opening of Global-Scale Vaccine Center in South Korea

作者: CN-INFO   责任编辑:文传商讯 2021-12-01 13:57:00
来源:文传商讯关键字:null

SINGAPORE -- (BUSINESS WIRE) --

Prestige BioPharma Limited (PBP, 950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, is pleased to announce the grand opening of its global-scale Vaccine Center in Osong, South Korea.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006182/en/

The opening ceremony was held on December 01, 2021 at the Vaccine Center in Osong Campus. The ceremony was attended by many distinguished guests including Minister for Government Policy Coordination Mr. Yun-cheol Koo, Deputy Governor Mr. Il-hong Seong of Chungbuk Province, Mayor of Cheongju City Mr. Beom-deok Han, Representatives from Octava Fund Limited Mr. Joseph Tey and Mr. Sze Khai Pang.

PBP commenced construction of its Vaccine Center April this year and completed the global-scale manufacturing facility with a total area of 10,342.88 m2 and a total capacity of 104,000 litres (52 units of 2,000 liter bioreactors) in only eight months by employing Prestige Biologics (334970: KOSDAQ)’ proprietary engineering technology, ALITA Smart BioFactoryTM. With the ALITA system which provides combined advantages of Stainless Steel & Single-Use system, different types of vaccines can be produced in versatile custom manufacturing suites. The Vaccine Center’s Single-Use bioreactors also enhance operational efficiency and productivity while minimizing the risk of cross contamination.

PBP is currently focusing on two COVID19 vaccine projects to produce Sputink V and Sputink Light vaccines. PBP’s global-scale Vaccine Center is capable of producing around 2.6 billion doses of the first dose of Sputnik V vaccine (Ad26 adenovirus vector) per year.

The center will soon be prepared to produce other types of vaccines including mRNA vaccines to actively respond to the growing demands of COVID19 vaccines.

The company ultimately aims to develop its own vaccine products to combat potential future pandemics and PBP Vaccine Center will be the basecamp for this journey.

PBP’s CEO, Dr Lisa S. Park commented, “We are very pleased to complete the Prestige Biopharma Vaccine Center as planned this year with our Group’s unique and unmatched engineering technology, ALITA Smart BioFactory” and “this Vaccine Center will be playing a significant role in our fight against Covid-19 and possible future pandemics”.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211130006182/en/

CONTACT:

Media enquiries:
Global Communication Team
Prestige BioPharma Ltd.
www.prestigebiopharma.com
Yujin Suh
Tel: +65-6924-6535
info@pbpsg.com
yujin.suh@prestigebio.com

Prestige Biopharma Vaccine Center (Photo: Business Wire)

The Tape Cutting Ceremony of Grand Opening of Prestige Biopharma Vaccine Center (Photo: Business Wire)

相关新闻:
网友评论(0) 评论仅代表网友个人观点,不代表CBINews观点。
CBINews网友您好,欢迎发表评论:(注册 后发表评论,可就本文发起辩论,将会获得更多关注)
 CBINews网友  注册邮箱:  

CBI 友情链接:

至顶网 |  腾讯科技 |  凤凰科技 |  商业伙伴 |  移动信息化 |  企业网 |  中国软件网 |  CIO时代网 |  更多>>

整合营销 |  CBINews刊例 |  《电脑商情报》刊例 |  联系方式 |  版权声明 |  友情链接

内容版权所有:电脑商情在线 北京米迪亚广告有限公司

地址:北京市海淀区中关村南大街28号6层 联系电话:(010)62178877-218

商务、内容合作QQ:15528356 客服电话:800-886-4689

电脑商情信息服务集团 成都华好网景科技有限公司

ICP证:川B2-20070068-5 川预审H8VZ-RBP6-X228-T60Z号 北京市公安局海淀分局备案编号:1101083710